FY25 Consolidated Revenue crosses Rs. 20,000 Crores milestone FY25 Healthcare Services Revenue crosses Rs. 10,000 Crores milestone
Q4 FY25 Consolidated Revenues grew 13% YoY to Rs. 5,592 Crores FY25 Consolidated Revenues rose 14% YoY to Rs. 21,794 Crores
Q4 FY25 Consolidated EBITDA increased 20% YoY to Rs. 770 Crores FY25 Consolidated EBITDA increased 26% YoY to Rs. 3,022 Crores
Q4 FY25 Consolidated PAT at Rs. 390 Crores, 54% YoY Growth FY25 Consolidated PAT at Rs. 1,446 Crores, 61% YoY Growth
Final Dividend of Rs. 10 per share, making for a Total Dividend of Rs. 19 per share, on face value of Rs. 5 per share.
Announces significant expansion in the Sarjapur micro-market through the addition of 700 beds in 2 stages, to establish a dominant presence in the south-eastern part of Bengaluru with wide addressable market.
Stage 1: Acquisition of an existing 200 bedded hospital (leased facility). Stage 2: Establishing a 500-bed greenfield hospital in close proximity
With the ongoing brownfield expansions in the city, the total bed strength in Bengaluru will be ~ 1,500 beds.
Brownfield expansion in Hyderabad by 160 beds through brownfield expansion at the existing Jubilee Hills and Secunderabad facilities.
Along with the upcoming facility in Gachibowli, Apollo Hospitals bed strength in Hyderabad will be
~1,400 beds.
With these announcements, Apollo Hospitals commits to adding over 4,300 beds over a period of 3 to 4 years, beginning FY26 with a total capital outlay of over Rs. 8,000 crores, with a balance capital outlay of over Rs. 6,000 crs.
Apollo Hospitals crossed the landmark milestone of 25,000 transplants across its network, reaffirming its leadership in complex, high-acuity care.
Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said: “At Apollo, our mission has always gone beyond treating illness—it is about enabling every individual to live a healthier, happier life. FY25 was a defining year. With revenues crossing ₹20,000 crores and Healthcare Services surpassing ₹11,000 crores, we are humbled by the trust placed in us across India and beyond.
Technology expanded the possibilities of healing, but compassion remained our foundation. A strong rise in patient volumes is a testament to the deep confidence people have in Apollo’s care and our differentiated Centers of Excellence. As we grow, our focus remains unwavering—making advanced, high- quality care accessible and affordable to all.
To address the rising burden of non-communicable diseases, we are intensifying our preventive care mission. Through Apollo ProHealth, we are set to globally launch pioneering wellness programs that redefine the healthcare landscape — shifting the focus from reactive treatment to proactive, preventive care.
Innovation remains our most powerful ally — from AI-powered diagnostics to precision robotic surgeries, all enabled by a digital backbone that is reimagining the entire patient- care journey, enabling care that is predictive, personalised, and scalable.
We are committed to growth and to the enhancement of our care touchpoints, with new hospitals to be commissioned this year in Pune, Kolkata, Hyderabad, Bangalore and Delhi NCR — and several more in varying stages of development. These state-of-the-art facilities will be equipped with cutting-edge medical technology, reinforcing our commitment to delivering world-class care at scale. Our over ₹8,000 crore investment over the next five years will add over 4,300 beds, with the first phase of ~ 2,000 beds already in progress—bringing advanced care closer to communities across India.
We are heartened by the performance of Apollo Health Co and AHLL, two strong pillars of the integrated care network we have created for the consumer. Apollo Pharmacies crossed 6,600 stores this year and Apollo 24|7 commenced distribution of Insurance products to increase access to care. AHLL has strengthened its capability through its Global Reference Labs and highly specialized test menu updated for the latest medical advancements.
But what truly drives Apollo forward is our people—the doctors, nurses, and caregivers who carry our legacy in every life they touch. Their commitment is creating a healthcare system that is not only clinically world-class but also deeply human.
As we step into FY26, our purpose remains clear: to touch a billion lives, lead with innovation and empathy, and help build a healthier, stronger India for future generations.”
Q4FY25 CONSOLIDATED RESULTS
Q4FY25 Revenues grew 13% YoY to Rs. 5,592 Crores;
· Healthcare Services (HCS) Revenue at Rs. 2,822 Crores; 10% YoY growth
· AHLL Revenues at Rs. 394 Crores; 11% YoY growth
· Apollo HealthCo Revenues at Rs. 2,376 Crores; 17% YoY growth
· GMV of Apollo 24/7 at Rs. 795 Crores
EBITDA
Q4FY25 Consolidated EBITDA grew 20% YoY to Rs. 770 Crores;
· Healthcare Services (HCS) EBITDA at Rs. 686 Crores; 16% YoY growth
· AHLL EBITDA at Rs. 47 Crores; 32% YoY growth
· Apollo HealthCo EBITDA at Rs. 36 Crores
PAT
Q4FY25 Consolidated PAT grew 54% YoY to Rs. 390 Crores;
· Healthcare Services (HCS) PAT at Rs. 385 Crore; 37% YoY growth
· AHLL PAT loss of Rs. 4 Crores
· Apollo HealthCo PAT at Rs. 9 Crores
FY25 CONSOLIDATED RESULTS
REVENUE
FY25 Revenues grew 14% YoY to Rs. 21,794 Crores;
· Healthcare Services (HCS) Revenue at Rs. 11,147 Crores; 13% YoY growth
· AHLL Revenues at Rs. 1,554 Crores; 14% YoY growth
· Apollo HealthCo Revenues at Rs. 9,093 Crores; 16% YoY growth
· GMV of Apollo 24/7 at Rs. 3,007 Crores
EBITDA
FY25 Consolidated EBITDA grew 26% YoY to Rs. 3,022 Crores;
· Healthcare Services (HCS) EBITDA at Rs. 2,701 Crores; 15% YoY growth
· AHLL EBITDA at Rs. 154 Crores; 32% YoY growth
· Apollo HealthCo EBITDA at Rs. 168 Crores
PAT
FY25 Consolidated PAT grew 61 % Yo Y to Rs. 1,446 Crores;
· Healthcare Services (HCS) PAT at Rs. 1,426 Crores; 25% YoY growth
· AHLL PAT loss of Rs. 27 Crores
· Apollo HealthCo PAT at Rs. 47 Crores
Financial Performance – Q4FY25
Consolidated Q4FY25 Performance
o Revenues at Rs. 55,923 mn vs Rs.49,439 mn in Q4 FY24; 13% YoY growth
o EBITDA grew by 20% at Rs. 7,699 mn vs Rs.6,405 mn in Q4 FY24. This is after Apollo 24/7 cost of Rs. 1 ,603 mn in the quarter (incl. Rs. 455 mn non-cash ESOP charge) vs Rs 1,508 mn in Q4 FY24.
o Reported PAT at Rs. 3,897 mn vs Rs.2,538 mn in Q4 FY24; 54% YoY growth
o Diluted EPS of Rs. 27.10 per share in Q4 FY25 (not annualized)
Healthcare service Q4FY25 Performance
o Revenue at Rs. 28,220 mn vs Rs. 25,626 mn in Q4 FY24; 10% YoY growth
o EBITDA grew by 16% at Rs. 6,863 mn vs Rs. 5,931 mn in Q4 FY24; Margins at 24.3% in Q4 FY25
o PAT stood at Rs. 3,852 mn vs Rs. 2,803 mn in Q4 FY24, 37% YoY growth
Apollo Health and Lifestyle Limited Q4FY25 Performance
o Revenue at Rs. 3,940 mn vs Rs. 3,547 mn in Q4 FY24; 11% YoY growth
o EBITDA grew by 32% at Rs. 472 mn vs Rs. 357 mn in Q4 FY24; Margins at 12.0% in Q4 FY25
o PAT loss of Rs. 43 mn vs loss of Rs. 87 mn in Q4 FY24
Apollo HealthCo Q4FY25 Performance
o Revenue at Rs. 23,763 mn vs Rs. 20,267 mn in Q4 FY24; 17% YoY growth
o EBITDA at Rs. 363 mn vs Rs. 117 mn in Q4 FY24; Margins at 1.5 % in Q4 FY25
o PAT stood at Rs. 88 mn vs loss of Rs. 177 mn in Q4 FY24
Financial Performance – FY25
Consolidated FY25 Performance
o Revenues at Rs. 217,940 mn vs Rs. 190,592 mn in FY24; 14% YoY growth
o EBITDA grew by 26% at Rs. 30,219 mn vs Rs. 23,907 mn in FY24. This is after Apollo 24/7 cost of Rs. 5,857 mn in FY25 (incl. Rs. 1,076 mn non-cash ESOP charge) vs Rs. 7,077 mn in FY24.
o Reported PAT at Rs. 14,460 mn vs Rs.8,986 mn in FY24; 61% YoY growth
o Diluted EPS of Rs. 100.56 per share in FY25
Healthcare service FY25 Performance
o Revenue at Rs. 111,475 mn vs Rs. 98,670 mn in FY24; 13% YoY growth
o EBITDA grew by 15% at Rs. 27,005 mn vs Rs. 23,558 mn in FY24; Margins at 24.2% in FY25
o PAT stood at Rs. 14,261 mn vs Rs. 11,450 mn in FY24, 25% YoY growth
Apollo Health and Lifestyle Limited FY25 Performance
o Revenue at Rs. 15,535 mn vs Rs. 13,653 mn in FY24; 14% YoY growth
o EBITDA grew by 32% at Rs. 1,538 mn vs Rs. 1,166 mn in FY24; Margins at 9.9% in FY25
o PAT loss of Rs. 270 mn vs loss of Rs. 508 mn in FY24
Apollo HealthCo FY25 Performance
o Revenue at Rs. 90,930 mn vs Rs. 78,269 mn in FY24; 16% YoY growth
o EBITDA at Rs. 1,676 mn vs loss of Rs. 817 mn in FY24; Margins at 1.8% in FY25
o PAT stood at Rs. 469 mn vs loss of Rs. 1,957 mn in FY24
Q4FY25 Segment-wise Performance Update
Healthcare Services (Hospitals)
As on March 31, 2025, Apollo Hospitals had 8,025 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% vs 65% in the same period in the previous year. IP volumes grew 4% in Q4 FY25 – and is the penultimate quarter which bears the base impact of Bangladesh patients, given the drop-off resulting from the change in Bangladesh government and pursuant change in visa application and norms.
Consolidated Revenues of the healthcare services division grew by 10% to Rs. 28,220 million in Q4 FY25 compared to Rs.25,626 million in Q4 FY24.
EBITDA (Post Ind AS 116) was at Rs. 6,863 million in Q4 FY25 compared to Rs. 5,931 million in Q4 FY24. EBITDA grew 16% YoY.
Revenues in the Tamil Nadu cluster grew by 7%, IP Volumes grew by 1%. ARPOB grew by 4% to Rs. 78,133. Overall occupancy in the cluster was 1337 beds (65% occupancy) as compared to 1,288 beds (63% occupancy) in the previous year.
In AP Telangana region, Revenues grew by 19%, IP volumes grew by 10%. ARPOB grew by 8% to Rs. 65,572. Occupancy in the cluster was 788 beds (64% occupancy) as compared to 712 beds (56% occupancy) in the previous year.
In Karnataka region, Revenues grew by 15%, IP volumes grew by 2%. ARPOB grew by 10% to Rs.70,598. Occupancy in the cluster was 538 beds (70% occupancy) as compared to 512 beds (68% occupancy)
